MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ...
Telix’s Illuccix prostate cancer PSMA-PET imaging agent approved in the Netherlands: Melbourne, Australia Wednesday, March 19, 2025, 12:00 Hrs [IST] Telix, a biopharmaceutical c ...
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the Brazilian Health ...
Brazilian Health Regulatory Agency (ANVISA) has granted approval for Telix Pharmaceuticals’ Illuccix, a prostate cancer imaging agent. Illuccix claims to be the first prostate-specific membrane ...
Brazil's health regulators have approved Telix Pharmaceuticals' nuclear imaging agent for prostate cancer, Illucix.
Great-West Lifeco (GWO) has released an update for its Supplemental Information Package (SIP) for 2025 for analysts and ...
HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the launch of their first Laboratory Developed Test (LDT) FibroSIGHTtm ? now ...